Use of Etanercept in a Series of Pediatric Patients With Stevens-Johnson Syndrome–Toxic Epidermal Necrolysis Spectrum Disease

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening adverse drug reactions that manifest with full-thickness epidermal necrosis and are often accompanied by fever and other systemic symptoms.^1,2 These entities exist on a disease spectrum (herein referred to as SJS-TEN) based on percentage of body surface area with denuded skin.³ Given the rarity of SJS-TEN in the pediatric population, there is no clear, evidence-based therapeutic recommendation beyond discontinuation of the harmful medication and burn-level supportive care.